Determination Of Catecholamines In Urine Research Articles

Determination of three urinary catecholamines and serotonin by on-line packed-fiber solid-phase extraction

生物单胺包括儿茶酚胺类以及5-羟色胺等,在中枢神经系统中扮演着非常关键的角色,也是临床上诊断神经内分泌肿瘤疾病的重要生物标志物。由于这类单胺类物质的强化学极性导致传统吸附材料对其吸附效果不佳,从复杂生物样本中同时检测更多的生物单胺存在挑战性。该文建立了一种基于聚冠醚纳米纤维在线固相萃取检测尿液中3种儿茶酚胺(多巴胺、肾上腺素、去甲肾上腺素)和5-羟色胺的方法。采用静电纺丝法制备聚二苯并-18-冠-6醚-聚苯乙烯复合纳米纤维(PCE-PS),制成装填纤维的固相萃取(PFSPE)柱,再将PFSPE柱与HPLC进行在线联用。该在线PFSPE-HPLC方法采用双三元泵进行样品富集净化和分析,左泵连接PFSPE柱,进行样品富集净化;右泵连接分析柱进行样品分离检测。控制切换阀的切换,实现样品富集后洗脱至分析柱中分离检测。结果表明,在线PFSPE-HPLC检测尿液儿茶酚胺(多巴胺、肾上腺素、去甲肾上腺素)和5-羟色胺在1~200 ng/mL范围内有良好的线性关系,线性相关系数达0.996以上。3种儿茶酚胺和5-羟色胺的检出限(S/N=3)分别为1和2.5 ng/mL,定量限(S/N=10)分别为2.5和5 ng/mL。空白尿液和实际尿液加标回收率在83.5%~117.7%之间,日内精密度<10%。PCE-PS复合纳米纤维在多次使用后无明显变化,具有良好的稳定性,可重复使用达95次以上。在线PFSPE-HPLC方法能够集样品在线前处理与分析检测于一体,省时省力,实现分析过程的高度自动化。该方法成功应用于尿液中3种儿茶酚胺和5-羟色胺的检测,可以为临床上相关疾病检测诊断和研究提供有力的技术支持。

Automated on-line packed fiber solid phase extraction for determination of urinary catecholamines

Despite the development of an off-line packed fiber solid phase extraction procedure (PFSPE) for urinary catecholamines, automation remains a challenge. Here, we propose an on-line PFSPE-HPLC procedure for automated sample processing and analysis of urinary catecholamines, with good recovery and precision, to avoid manual operation errors. The on-line PFSPE-HPLC procedure has been thoroughly optimized concerning the gradient, valve switch timing, the effects of complexing reagent and buffer solution, and the stability of the nanofibers. Validation of the developed on-line PFSPE-HPLC protocol in urine yielded satisfactory accuracies of 99.6–104.2%, precision below 7.0%, as well as a linear range from 1 ng/mL to 100 ng/mL with a correlation coefficient of 0.999. The developed protocol is herein presented as a potential technology for automated sample pretreatment for the determination of urinary catecholamines.

LC–MS/MS Determination of Catecholamines in Urine Using FMOC-Cl Derivatization on Solid-Phase Extraction Cartridge

A method for the determination of catecholamine derivatives in human urine is proposed that includes the derivatization of target compounds on a solid-phase extraction cartridge and determination of the analytes by a UHPLC method with tandem mass-spectrometric detection. 9-Fluorenyl-methoxycarbonyl chloride was used as the derivatization agent. The limits of detection for the analytes were 2.5 ng mL−1 for 9-fluorenyl-methoxycarbonyl-adrenaline, 5 ng mL−1 for 9-fluorenyl-methoxycarbonyl-octopamine, and 25 ng mL−1 for 9-fluorenyl-methoxycarbonyl-dopamine. The proposed procedure was tested on real samples obtained from volunteers.

Determination of urinary catecholamines and metanephrines in cardiac deaths.

The aim of this study was to measure catecholamines and their O-methylated metabolites in urine and vitreous humor collected in cardiac deaths and noncardiac control cases that underwent medicolegal investigations. Our first goal was to assess whether cardiac events of different types are characterized by different catecholamine/metanephrine urine and/or vitreous profiles. Our second goal was to determine whether noncardiac causes of death with different survival intervals are characterized by different catecholamine/metanephrine urine and/or vitreous profiles. Two study groups were prospectively and retrospectively formed, a cardiac death group (including three subgroups, according to the cause of death) and a noncardiac death group (including two subgroups, according to the length of the agonal period). Postmortem angiography, autopsy, histology, toxicology, and biochemistry were performed in all cases. First results seem to indicate that absolute values measured in urine and vitreous for each of the analyzed markers display no significant differences relating to each of the tested cardiac death subgroups. In the control group, absolute concentrations measured in urine and vitreous for each of the analyzed parameters failed to show significant differences relating to the length of agonal period. Our preliminary findings do not seem to confirm the conclusions of former studies and fail to corroborate the usefulness of urine catecholamine and metanephrine analysis to characterize stress response intensity or length of the dying process in the postmortem setting.

Establishment of a LC-MS/MS for the determination of urinary catecholamines

Establishment of a LC-MS/MS for the determination of urinary catecholamines

Determination of catecholamines in urine using aminophenylboronic acid functionalized magnetic nanoparticles extraction followed by high-performance liquid chromatography and electrochemical detection.

A new method was developed for the simultaneous determination of three catecholamines in urine using aminophenylboronic acid functionalized magnetic nanoparticles extraction followed by high-performance liquid chromatography with electrochemical detection. Novel aminophenylboronic acid functionalized magnetic nanoparticles were prepared by multi-step covalent modification, and characterized by transmission electron microscopy, Fourier-transformed infrared spectroscopy, X-ray diffraction, and vibrating sample magnetometry. With the help of the high affinity between the boronate and cis-diol group, the particles were used for the highly selective separation and enrichment of three major catecholamines, norepinephrine, epinephrine, and dopamine. Effects of the pH of the feed solution, the extraction time, the composition of the buffer solution, the amount of the magnetic particles, the elution conditions, and the recycling of aminophenylboronic acid functionalized magnetic nanoparticles were explored. Under the optimized conditions, 13-17-fold enrichment factors were obtained. The linear ranges were 0.01-2.0 μg/mL for the studied analytes. The limits of detection and quantification were in the range of 2.0-7.9 and 6.7-26.3 ng/mL, respectively. The relative recoveries were in the range of 92-108%, with intraday and interday relative standard deviations lower than 6.8%. This method was successfully applied to analysis of catecholamines in real urine.

Simultaneous Determination of Catecholamines and Metanephrines in Urine by Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry: Successful Clinical Application

Determination of urinary catecholamines and metanephrines is important for diagnosis of pheochromocytoma. Liquid chromatography tandem mass spectrometry (LC-MS/MS) method has been developed for the determination of catecholamines and metanephrines in human urine using deuterated internal standards (IS). In this method, 1000 µL of urine samples were treated by liquid-liquid extraction using ethyl acetate and subjected to LC-MS/MS analysis using positive electrospray ionization (ESI+). A BDS HYPERSILTM C18 column (125 mm × 3 mm, 3 µm) was used and mobile phase was water:methanol (98:2, v/v) with 0.25% of formic acid at 200 µ L min−1. The method has a chromatographic running time of approximately 10 min. The average of recovery was 92.9-106.1% for epinephrine, 94.6-107.7% for norepinephrine, 98.0-108.8% the dopamine, 94.2-105.1% the metanephrine, 97.0-106.0% for normetanephrine. The precision was lower than 7.0% for all analytes. Furthermore, this method has been implemented successfully in routine laboratory due to its easy execution and excellent precision.

A simple and sensitive CE method for the simultaneous determination of catecholamines in urine with in-column optical fiber light-emitting diode-induced fluorescence detection

A simple and sensitive method has been developed for simultaneous analysis of three catecholamines: dopamine (DA), epinephrine (EP) and norepinephrine (NE) in urine by capillary electrophoresis (CE) coupled with in-column fiber-optic light-emitting diode-induced fluorescence detection (ICFO-LED-IFD). Fluorescein isothiocyanate was used as the fluorescence tagged reagent for derivatization of DA, EP and NE. The CE conditions for separation of these catecholamines were systematically investigated. It was found that catecholamines could be more effectively separated by adding β-cyclodextin (β-CD) and acetonitrile (ACN) to a background electrolyte (BGE) of sodium borate. The migration times are 10.61, 10.83 and 11.14min for DA, EP and NE, respectively and the catecholamines are completely separated within 11.5min under the optimal condition of a BGE containing 10% v/v ACN, 20mM β-CD and 20mM sodium borate (pH 9.5), and an applied voltage of 13kV. The relative standard deviations of migration time and peak area for these catecholamines are less than 0.16 and 2.0%, respectively. The limit of quantifications (LOQs) for DA, EP and NE are 3.5, 1.0 and 3.1nM whereas the limit of detections (LODs) for DA, EP and NE are 1.0, 0.3 and 0.9nM, respectively. Our proposed CE method provides low LOQ and LOD values. This CE-ICFO-LED-IFD methodology has been successfully applied to analyze catecholamines in human urine samples with good accuracy and satisfactory recovery.

Blood Pressure Changes After Automatic and Fixed CPAP in Obstructive Sleep Apnea: Relationship with Nocturnal Sympathetic Activity

Treatment of obstructive sleep apnea (OSA) by continuous positive airway pressure (CPAP) usually causes a reduction in blood pressure (BP), but several factors may interfere with its effects. In addition, although a high sympathetic activity is considered a major contributor to increased BP in OSA, a relationship between changes in BP and in sympathetic nervous system activity after OSA treatment is uncertain. This study was undertaken to assess if, in OSA subjects under no pharmacologic treatment, treatment by CPAP applied at variable levels by an automatic device (APAP) may be followed by a BP reduction, and if that treatment is associated with parallel changes in BP and catecholamine excretion during the sleep hours. Nine subjects underwent 24-h ambulatory BP monitoring and nocturnal urinary catecholamine determinations before OSA treatment and 2 months following OSA treatment by APAP (Somnosmart2, Weinmann, Hamburg, Germany). Eight control subjects were treated by CPAP at a fixed level. After APAP treatment, systolic blood pressure (SBP) decreased during sleep (p < 0.05), while diastolic blood pressure (DBP) decreased both during wakefulness (p < 0.05) and sleep (p < 0.02). Similar changes were observed in subjects receiving fixed CPAP. Nocturnal DBP changes were correlated with norepinephrine (in the whole sample: r = .61, p < 0.02) and normetanephrine (r = .71, p < 0.01) changes. In OSA subjects under no pharmacologic treatment, APAP reduces BP during wakefulness and sleep, similarly to CPAP. A reduction in nocturnal sympathetic activity could contribute to the reduction in DBP during sleep following OSA treatment.

Determination of catecholamines in urine using hydrophilic interaction chromatography with electrochemical detection

The determination of catecholamines in urine was investigated using hydrophilic interaction chromatography (HILIC) as an alternative to the commonly used reversed-phase (RP) method. A number of different approaches were explored, including per-aqueous liquid chromatography (PALC), and HILIC using bare silica, bonded amide and zwitterionic phases. The bonded phases gave superior results in terms of both peak shape and selectivity. The mechanism of the HILIC separation was investigated particularly with respect to the contribution of ion exchange to retention. The electrochemical detection of catecholamines was studied and optimised in typical HILIC mobile phases that contain high concentrations of acetonitrile. HILIC offered a number of advantages over the conventional RP approach, giving good retention of the solutes without use of ion pair reagents, the absence of which also would facilitate detection by mass spectrometry. HILIC used in conjunction with solid phase extraction based on RP also gives orthogonal separation mechanisms in the cleanup and analysis steps. Furthermore, good recoveries from the cleanup stage were obtained, as high concentrations of acetonitrile can be used as eluting solvent that are fully compatible with HILIC, and lipophilic impurities are eluted close to the void volume of the HILIC column.

Maturation of the Sympatho-Adrenal System and Clinical Values of the Determination of Urinary Catecholamine Excretion

Sympatho-adrenal system function was assessed in various age groups of normal subjects and in infants with some abnormal conditions, by assays of daily urinary catecholamine excretion. The urinary catecholamine excretion was prone to increase postnatally with time. The group of children aged 1 to 5 years exhibited a significantly greater urinary catecholamine excretion than the group of newborn infants. No significant difference concerning urinary catecholamine excretion was observed among three age groups, 1–5, 6–10 and 10–20 years of age. This finding is related to rapid growth and maturation of the sympatho-adrenal system in early life with increased catecholamine excretion. Moreover, the urinary catecholamine excretion was remarkably increased at symptomatic exacerbation and declined to a normal level with alleviation of symptoms in a case of respiratory distress syndrome. The present communication is the first to demonstrate the usefulness of urinary catecholamine determination in newborn infants.

Dipyrone (Metamizole) Metabolites Interfere with HPLC Analysis of Plasma Catecholamines but Not with the Determination of Urinary Catecholamines

Catecholamines and their metabolites are measured for the diagnosis of pheochromocytoma(1)(2) and neuroblastoma(3) and for various other reasons(4)(5)(6). The widely used HPLC assay, which uses electrochemical detection (ECD), combines high selectivity and sensitivity(7). The internal standard, 3,4-dihydroxybenzylamine (DHBA), is added before analysis. After pretreatment with a sample clean-up column, catecholamines are separated and quantified by HPLC-ECD. Commercial methods (Chromsystems) elute norepinephrine, epinephrine, DHBA, and dopamine at 8, 9, 12–13, and 17–19 min, respectively. The next sample is injected after 25 min. We sometimes observed an unknown peak in the plasma catecholamine chromatogram that interfered with the internal standard DHBA (Fig. 1A⇓ ). When we repeated the analysis, the spurious extra peak disappeared (Fig. 1B⇓ ). When we evaluated the medical histories of these patients, we found that for a preceding analysis they had received dipyrone orally or intravenously within 12 h before blood collection. Therefore, we hypothesized that administration of dipyrone and/or its metabolites may have led to the interference with DHBA in the subsequent analysis. Figure 1. HPLC chromatograms of plasma catecholamines. (A) Chromatographic separation of plasma catecholamines from patients yielded chromatograms with an additional peak …

Cardiac Rhythm Disturbances and ST-Segment Depression Episodes in Patients With Obstructive Sleep Apnea-Hypopnea Syndrome and Its Mechanisms

<h3>Study objectives</h3> To compare the frequency of daytime and nocturnal cardiac arrhythmias and ST-segment depression episodes among patients with obstructive sleep apnea-hypopnea syndrome (OSAHS), snoring subjects, and healthy subjects, and to analyze the relationship between the cardiac disturbances, sleep characteristics, and sympathetic tone in patients with OSAHS. <h3>Patients and interventions</h3> Twenty-one consecutive patients with OSAHS, 12 snorers without hypersomnolence, and 15 healthy subjects were selected. Polysomnography, 24-h Holter ECG recording, and urinary catecholamine determination were simultaneously performed on all subjects. <h3>Results</h3> Patients with OSAHS had more daytime and nocturnal episodes of sinus and supraventricular arrhythmias and couplets than the snoring and control groups. Moreover, nocturnal ST-segment depression episodes were more frequent in the OSAHS group than in control subjects (0.565 ± 0.826/h vs 0 ± 0/h [mean ± SD]). In patients with OSAHS, arousal index and daytime epinephrine levels were related to daytime and nocturnal ST-segment depression episodes, whereas minimum arterial oxygen saturation was related to nocturnal sinus bradycardia and supraventricular tachycardia. Epinephrine and norepinephrine urinary concentrations correlated with sinus and supraventricular arrhythmias. <h3>Conclusions</h3> Patients with OSAHS have a higher frequency of cardiac rhythm disturbances and ST-segment depression episodes than snoring and control subjects. Moreover, ST-segment changes are related to sympathetic tone and sleep fragmentation, whereas most of the rhythm disturbances in patients with OSAHS are associated with sleep fragmentation, nocturnal hypoxemia, and sympathetic tone.

Quantifying catecholamines using multi-way kinetic modelling

A new method for quantifying adrenaline and noradrenaline concentrations from mixtures of catecholamine standards is described. The method derives selectivity from the different rates, at which the fluorescing 3,5,6-trihydroxyindole derivatives (lutines) of the catecholamines are formed and degraded for adrenaline and noradrenaline. The standards used had the concentration ranges 50–1200 nmol/l for adrenaline and 30–1400 nmol/l for noradrenaline. Fluorescence landscapes were measured at consecutive time points for every sample hereby creating a four-way data array. It is shown that the raw dataset can be dramatically reduced in size without loosing significant information hereby making calculations much faster and lessening instrumental performance requirements. The data follow a two-component four-way parallel factor analysis model (PARAFAC), from which quantitative information is also obtained. Two-component multilinear partial least squares regression ( N-PLSR) was also employed for the quantification of the catecholamines. The results for PARAFAC and N-PLSR were very similar with root mean squared errors of cross-validation (RMSECV) being in the range 24–30 nmol/l. Several improvements of the method are suggested, and it is expected that the method will be suitable for determination of catecholamines in urine from healthy subjects.

Analysis of Catecholamines in Urine by Positive-Ion Electrospray Tandem Mass Spectrometry

Determination of urinary catecholamines (CATs) is considered important for clinical diagnosis of pheochromocytoma, paraganglioma, and neuroblastoma. The major disadvantages of existing tests include relatively long instrumental analysis time and potential interference from drugs and drug metabolites that are structurally similar to CATs. CATs were extracted from a 300-microL aliquot of urine by a two-step liquid-liquid extraction method specific for compounds containing a catechol group. Chromatographic separation did not require the use of ion-pairing reagents, which typically hinder MS detection but are frequently used in HPLC analysis of CATs. Instrumental analysis was performed by electrospray ionization tandem mass spectrometry (ESI-MS/MS) in the multiple-reaction monitoring mode. Stable-isotope-labeled CATs were used as internal standards. Epinephrine (E), norepinephrine (NE), and dopamine (D) were measured within 3.5 min instrumental run time. Quantification limits were 2.5 microg/L for E and D and 10 microg/L for NE. The total imprecision (CV) was < or =9.6%; extraction recoveries were 71% +/- 12%. HPLC with ESI-MS/MS in combination with sample preparation specific to catechol group-containing compounds allows rapid testing for disorders associated with increased CAT concentrations. The method is free of interferences from drugs and drug metabolites, which commonly interfere with HPLC methods.

Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study.

The aim of this prospective study is to update our knowledge of the chronology of pheochromocytoma occurrence in multiple endocrine neoplasia type 2 (MEN 2), and to better manage MEN 2 patients after the genetic diagnosis. Eighty-seven non-index gene carrier MEN 2 patients were included in this prospective study: 84 patients with MEN 2A (from 52 families) and 3 with MEN 2B (from 3 families). Medullary thyroid carcinoma (MTC) was diagnosed by measuring plasma calcitonin in basal conditions or after pentagastrin stimulation. The search for pheochromocytoma consisted of clinical evaluation, 24 h determination of urinary catecholamines and adrenal imaging. The mean age at genetic diagnosis of MEN 2 was 14.0+/-7.0 years, the mean duration for the follow-up was 7.6+/-2.8 years. All 87 patients had a MTC detected at the same time as the genetic diagnosis was made. Urinary catecholamine measurements led to the diagnosis of pheochromocytoma and a combination of imaging techniques enabled the correct localization of both unilateral or bilateral adrenal involvement. Pheochromocytoma was detected simultaneously with MTC in only seven patients, and seven others were detected throughout the follow-up. Of the 14 patients with pheochromocytoma, 11 had bilateral involvement: nine were initially bilateral and two became so during follow-up. This study demonstrates that in MEN 2, MTC is the lesion which appears earliest. Pheochromocytoma develops later during the evolution of the disease, and necessitates regular clinical and biological monitoring throughout follow-up. Determination of urinary and/or plasma catecholamines and metanephrines should be performed to detect pheochromocytoma. Imaging techniques lead to the detection of both unilateral and bilateral pheochromocytoma, thus making video-assisted laparoscopic adrenalectomy possible.

Determination of urinary catecholamines with capillary electrophoresis after solid-phase extraction

The stabilities of 3,4-dihydroxybenzylamine (DHBA), dopamine, 3-methoxytyramine, normetanephrine and metanephrine standards under acid, base and enzymatic hydrolysis conditions were studied. Basic incubation media were not suitable for 3,4-dihydroxy compounds, but acid and enzymatic hydrolysis conditions were applicable to all the compounds. The results of acid and enzymatic hydrolysis were comparable and the enzymatic hydrolysis was applied to a urine matrix. A method including solid-phase extraction (SPE) with a copolymer sorbent was developed for purification of the urine samples. Due to poor recovery of DHBA, the most frequently used internal standard in catecholamine analysis, this compound was replaced with the 3- O-methoxy structure. The recoveries of the compounds in spiked urine samples in SPE were between 96.4 and 124.4%. The repeatability of the combination of enzymatic hydrolysis and SPE pretreatment was good for all the compounds, except for dopamine and 3-methoxytyramine due to some matrix compounds still interfering with the separation. The analyses were performed with capillary electrophoresis in an ammonium acetate buffer with UV detection. The validation data for the compounds including limit of detection, limit of quantification, linearity and repeatability of the method are presented.

Analytical interference of drugs on the fluorimetric determination of urinary catecholamines

Analytical interference of drugs on the fluorimetric determination of urinary catecholamines

Simultaneous determination of urinary catecholamines and 5-hydroxyindoleamines by high-performance liquid chromatography with fluorescence detection.

A simple, selective and sensitive high-performance liquid chromatographic method with fluorescence detection is described for the simultaneous determination of catecholamines and 5-hydroxyindoleamines. The method is based on the derivatization of the amines with benzylamine in the presence of potassium hexacyanoferrate(III) under mild conditions. The resulting fluorescent derivatives are separated on a reversed-phase column, Cosmosil 5C18, using a mixture of acetonitrile and 10 mmol l-1 acetate buffer (pH 6.0) (35 + 65 v/v) as mobile phase, and are detected spectrofluorimetrically at 480 nm with excitation at 345 nm. The detection limits (signal-to-noise ratio = 3) for the amines are 2.8-236.0 fmol for an injection volume of 50 microliters. The method was successfully applied to the determination of 5-hydroxyindol-3-ylacetic acid, serotonin, norepinephrine and epinephrine in human urine. The method is simple and does not require clean-up of urine samples.

Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas)

Since 1989, 45 patients [pts; 26 females and 19 males, aged 19-79 yr (median, 58)] bearing incidentally discovered adrenal masses were studied. The aim of the study was to verify the prevalence of hormone activity in clinically silent adrenal masses. Endocrine work-up included determination of urinary catecholamines and their metabolites, measurement of PRA and aldosterone levels in clino- and orthostatic posture, and basal and dynamic [dexamethasone (dex) suppression and ovine CRH stimulation] evaluation of hypothalamic-pituitary-adrenal axis. The most frequent finding was the reduction of dehydroepiandrosterone sulfate (DHEA-S) levels below the third percentile of controls in 19 (42%) pts. DHEA-S levels were significantly lower in pts than in controls [68 (range, 5-1000) vs. 208 (34-326) micrograms/dL; 1.8 (0.1-27.1) vs. 5.6 (0.9-8.8) mumol/L; P < 0.001]. Three pts (7%) had high 24-h mean serum cortisol levels, and 6 (14%) had blunted day-night amplitude of cortisol rhythm. Defective dex suppressibility was found in 15% of pts vs. 8% of controls (P < 0.05). ACTH and cortisol responses to ovine CRH did not significantly differ between pts and controls, although blunted ACTH responses were found in 22% of the cases. The above-mentioned endocrine alterations could be accounted for by autonomous cortisol secretion by the adrenal nodule at a rate not sufficient to give clinical expression, but able to inhibit to some extent the hypothalamic-pituitary-adrenal axis. These results indicate that silent cortisol hypersecretion is frequently observed in pts with adrenal incidentaloma even if progression to overt Cushing's syndrome seems unlikely. Indeed, the size of the mass and the hormone pattern remained substantially unchanged in 9 pts followed up for 12 months. From merely a cost/benefit ratio, the evaluation of DHEA-S levels and dex suppression has sufficient sensitivity to identify the occurrence of silent hypercortisolism.